ACCESS Newswire

Identillect Technologies Corp

22.7.2021 14:31:54 CEST | ACCESS Newswire | Press release

Share
Identillect Is Increasing Exposure With Bar Associations Through Sponsorship and Education

As the United States Bar Associations return to normal operations Identillect once again ramps up lecturing sponsorship for increased exposure.

DANA POINT, CA / ACCESSWIRE / July 22, 2021 / Identillect Technologies Corp. (the 'Company' or 'Identillect') (TSXV:ID), a leading provider of email security, and the leading secure email provider for Bar Associations across the United States announced today that it is increasing its exposure with the Bar Associations across the United States.

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

In April, Identillect sponsored the West Virginia State Bar's Annual Meeting, and for the fourth year in a row, Todd Sexton, Identillect's CEO, presented at Arkansas Bar Association's Annual Meeting. Also in June, Identillect sponsored the State Bar of Nevada's Annual Meeting for the first year.

On July 23rd, Todd will present alongside Brad Andrews, General Counsel to the Idaho State Bar at the State Bar's Annual Meeting in Boise. This will be the second year in a row the two will be presenting together and educating members on cybersecurity threats in addition to their duties to protect their client's confidential information.

Next month, Identillect will present a cybersecurity CLE lecture for members of the Wyoming State Bar, and in September, Identillect will sponsor the Wyoming State Bar's Annual Meeting. These are just of few of the marketing initiatives Identillect with engage in throughout the remainder of 2021.

Identillect is continually serving the legal community and is partnered with 19 states bars for their cyber security needs and assists with the education for advanced understanding of threats and providing the product solutions to thwart these intrusions.

About Identillect
Identillect Technologies is the leading provider of email encryption service Delivery Trust ® , empowering enterprises of all sizes to protect their business and their client's critical information against cyber security attacks.

Delivery Trust ® is an award-winning, multi-platform plug-in, which gives users complete control of their emails, for one low price. The simple integration complies with all regulations and most importantly provides peace of mind.

For more information, or your free trial, please visit www.identillect.com.

On Behalf of the Board of Directors of:

IDENTILLECT TECHNOLOGIES CORP.

Todd Sexton
Chief Executive Officer
Tel: (949) 468-7878
Email: todd.sexton@identillect.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.

SOURCE: Identillect Technologies Corp



View source version on accesswire.com:
https://www.accesswire.com/656554/Identillect-Is-Increasing-Exposure-With-Bar-Associations-Through-Sponsorship-and-Education

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESS Newswire

DK

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

OBI Pharma Announces Ten Poster Presentations at the AACR 2026 Annual Meeting for GlycOBI(R) Glycan-based Site-Specific Antibody-Drug Conjugates (ADCs): Mono and Bi-Specific (inc. Dual payload) and Obrion(TM) ADC enabling technologies15.4.2026 10:40:00 CEST | Press release

Poster Presentations featuring the latest advancements on anti-TROP2 (OBI 902) and Nectin-4 (OBI 904) ADCs, anti-TROP2/HER2 BsADC (OBI 201), anti-cMET/HER3Bs-Dual Payload ADC (OBI 221),and OBI's novel Obrion ™ ADC enabling technologies(GlycOBI ® and GlycOBI DUO ®). TAIPEI, TW / ACCESS Newswire / April 15, 2026 / OBI Pharma, Inc. (TPEx:4174.TWO) today announced its presence at AACR 2026, highlighted by ten poster presentations, showcasing the transformative potential of the GlycOBI® platform. Conventional ADCs often face limitations due to random conjugation, resulting in heterogeneous Drug-to-Antibody Ratios (DAR), suboptimal stability, and narrow therapeutic windows. In contrast, the OBI site-specific glycan-based technology enables a highly homogeneous DAR, translating into improved PK/PD profiles, and reduced off-target toxicity, as demonstrated by OBI's lead programs, OBI-902 and OBI-904. We are further advancing precision oncology through our next-generation bispecific (OBI-201) a

OBI Pharma Announces Ten Poster Presentations at the AACR 2026 Annual Meeting for GlycOBI(R) Glycan-based Site-Specific Antibody-Drug Conjugates (ADCs): Mono and Bi-Specific (inc. Dual payload) and Obrion(TM) ADC enabling technologies15.4.2026 10:40:00 CEST | Press release

Poster Presentations featuring the latest advancements on anti-TROP2 (OBI 902) and Nectin-4 (OBI 904) ADCs, anti-TROP2/HER2 BsADC (OBI 201), anti-cMET/HER3Bs-Dual Payload ADC (OBI 221),and OBI's novel Obrion ™ ADC enabling technologies(GlycOBI ® and GlycOBI DUO ®). TAIPEI, TW / ACCESS Newswire / April 15, 2026 / OBI Pharma, Inc. (TPEx:4174.TWO) today announced its presence at AACR 2026, highlighted by ten poster presentations, showcasing the transformative potential of the GlycOBI® platform. Conventional ADCs often face limitations due to random conjugation, resulting in heterogeneous Drug-to-Antibody Ratios (DAR), suboptimal stability, and narrow therapeutic windows. In contrast, the OBI site-specific glycan-based technology enables a highly homogeneous DAR, translating into improved PK/PD profiles, and reduced off-target toxicity, as demonstrated by OBI's lead programs, OBI-902 and OBI-904. We are further advancing precision oncology through our next-generation bispecific (OBI-201) a

IDC Defines the Next Era of Technology Intelligence with the Introduction of IDC Quanta(TM) at Directions 20268.4.2026 17:15:00 CEST | Press release

New AI-powered platform establishes an embedded intelligence layer for the AI economy, delivering decision-grade insight BOSTON, MA / ACCESS Newswire / April 8, 2026 / IDC today opened IDC Directions 2026, its flagship client event, bringing together technology leaders, analysts, and industry experts to examine the forces reshaping the global technology market and to introduce a major evolution in how technology intelligence is delivered. At the center of this year's event is IDC Quanta™, a new AI-powered platform that establishes what IDC defines as the technology intelligence layer for the AI economy. As artificial intelligence accelerates the pace of business and compresses decision cycles, IDC is redefining its role from a destination for research and data to an embedded intelligence capability that delivers trusted insight directly into the workflows where decisions are made. "AI is compressing time across the entire technology market, and that breaks the traditional research mode

DistillerSR Launches the Industry's Most Advanced GenAI Capabilities for Extracting Scientific Literature Evidence8.4.2026 16:00:00 CEST | Press release

DistillerSR's Smart Evidence Extraction Now Fully Automates Text and Table Data at Scale OTTAWA, ON / ACCESS Newswire / April 8, 2026 / DistillerSR, the market leader in AI-enabled literature review automation and evidence management, today announced new fully automated capabilities for its Smart Evidence Extraction (SEE) module. SEE uses purpose-built GenAI to automate end‑to‑end workflows for extracting evidence from scientific literature at scale, while maintaining full auditability and human governance over AI‑generated outputs. As the volume of published research continues to grow exponentially, research teams in the pharmaceutical and medical device industries face increasing pressure to monitor evidence with speed and precision. SEE enables research professionals to accurately find, suggest, explain, extract, and link the supporting evidence within the reference in a human-in-the-loop and fully automated workflow. "The latest version of SEE is designed to move research teams fro

Envision Pharma Group appoints Nick Jones as President, Envision Medical Communications8.4.2026 14:00:00 CEST | Press release

Seasoned technology and life sciences leader to advance AI integration across medical communications FAIRFIELD, CT / ACCESS Newswire / April 8, 2026 / Envision Pharma Group (Envision), a global, technology-enabled solutions partner to the life sciences industry, today announced the appointment of Nick Jones as President, Envision Medical Communications (EMC). In this role, Jones will lead the EMC business, focusing on integrating Envision's industry-leading technology and AI capabilities into its award-winning portfolio of solutions and services. Jones joins the company from ConcertAI, where he served as Senior Vice President and General Manager, Commercial Solutions, leading teams delivering consulting services, AI-driven software-as-a-service solutions, and data products supporting pharmaceutical commercialization. Prior to ConcertAI, he spent over a decade at IQVIA (formerly IMS), leading technology and consulting organizations across the US, Europe, and JAPAC, delivering an integra

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye